Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD

April Armstrong; Leon Kircik; Ketty Peris; Melinda Gooderham; Sebastien Barbarot; Aleksandra Lesiak; Rie von Eyben; Niels Højsager Bennike; Ann-Marie Tindberg; Margitta Worm

doi:10.25251/26swpe94

April Armstrong

University of California Los Angeles, Los Angeles, CA, USA

Leon Kircik

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Ketty Peris

Università Cattolica del Sacro Cuore, Rome, Italy

Melinda Gooderham

SKiN Centre for Dermatology, Peterborough, ON, Canada

Sebastien Barbarot

University Hospital of Nantes, Nantes, France

Aleksandra Lesiak

Medical University of Lodz, Lodz, Poland

Rie von Eyben

LEO Pharma A/S, Ballerup, Denmark

Niels Højsager Bennike

LEO Pharma A/S, Ballerup, Denmark

Ann-Marie Tindberg

LEO Pharma A/S, Ballerup, Denmark

Margitta Worm

Charité Universitätsmedizin Berlin, Berlin, Germany

Keywords

atopic dermatitis, quality of life, tralokinumab, dosing frequency

Abstract

N/A

References

1. ADBRY (tralokinumab-ldrm). Prescribing information. LEO Pharma A/S; 2024. Accessed September 17, 2025.

2. Adtralza (tralokinumab). Summary of product characteristics (annex I). LEO Pharma A/S; 2025. Accessed September 17, 2025.

3. Simpson, EL, et al. Am J Clin Dermatol. 2023; 24(6):939–952.

4. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463.

6. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449.

PDF

Published

2026-03-10

DOI: https://doi.org/10.25251/26swpe94

How to Cite

Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. J of Skin. 2026;10(2):s731. doi:10.25251/26swpe94

Issue

Vol. 10 No. 2 (2026): March 2026 Issue

Section

Poster Presentations at 2026 Winter Clinical Dermatology Conference®: Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Andrew F. Alexis, Richard G. Fried, Evan Rieder, James Del Rosso, Leon Kircik, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Adelaide Hebert, Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Emma Guttman-Yassky, Alan Irvine, Eric Simpson, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan Silverberg, Heidi Crane, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Evangeline Pierce, Helena Agell, Diamant Thaçi, Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin , SKIN The Journal of Cutaneous Medicine: Vol. 9 No. 1 (2025): January 2025 Issue
Kristian Reich, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, Andrew Blauvelt, Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Danny Zakria, April Armstrong, Brian Berman, James Del Rosso, Mark Lebwohl, Todd Schlesinger, Darrell Rigel, The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt, 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)